The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Extrapulmonary Small Cell Carcinoma

Small cell carcinoma is a type of highly aggressive poorly differentiated neuroendocrine tumor that can arise from multiple organs, including but not limited to bronchial tissue, pancreas, gastrointestinal tract, and genitourinary system. The most commonly studied type is small cell lung cancer (SCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Aly, Ragia, Gupta, Sachin, Potdar, Rashmika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325398/
https://www.ncbi.nlm.nih.gov/pubmed/32617246
http://dx.doi.org/10.7759/cureus.8862
_version_ 1783552142632550400
author Aly, Ragia
Gupta, Sachin
Potdar, Rashmika
author_facet Aly, Ragia
Gupta, Sachin
Potdar, Rashmika
author_sort Aly, Ragia
collection PubMed
description Small cell carcinoma is a type of highly aggressive poorly differentiated neuroendocrine tumor that can arise from multiple organs, including but not limited to bronchial tissue, pancreas, gastrointestinal tract, and genitourinary system. The most commonly studied type is small cell lung cancer (SCLC) which carries the worst prognosis among lung cancers. After multiple promising clinical trials, the National Comprehensive Cancer Network has recently added atezolizumab and durvalumab in combination with platinum-based chemotherapy/etoposide to the first-line treatment regimen for extensive-stage SCLC (ES-SCLC). Meanwhile, the recommended treatment for extrapulmonary small cell carcinoma (EPSCC) remains unchanged. In this review, we try to explore the role of immunotherapy in the treatment of EPSCC.
format Online
Article
Text
id pubmed-7325398
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-73253982020-07-01 The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Extrapulmonary Small Cell Carcinoma Aly, Ragia Gupta, Sachin Potdar, Rashmika Cureus Oncology Small cell carcinoma is a type of highly aggressive poorly differentiated neuroendocrine tumor that can arise from multiple organs, including but not limited to bronchial tissue, pancreas, gastrointestinal tract, and genitourinary system. The most commonly studied type is small cell lung cancer (SCLC) which carries the worst prognosis among lung cancers. After multiple promising clinical trials, the National Comprehensive Cancer Network has recently added atezolizumab and durvalumab in combination with platinum-based chemotherapy/etoposide to the first-line treatment regimen for extensive-stage SCLC (ES-SCLC). Meanwhile, the recommended treatment for extrapulmonary small cell carcinoma (EPSCC) remains unchanged. In this review, we try to explore the role of immunotherapy in the treatment of EPSCC. Cureus 2020-06-27 /pmc/articles/PMC7325398/ /pubmed/32617246 http://dx.doi.org/10.7759/cureus.8862 Text en Copyright © 2020, Aly et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Oncology
Aly, Ragia
Gupta, Sachin
Potdar, Rashmika
The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Extrapulmonary Small Cell Carcinoma
title The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Extrapulmonary Small Cell Carcinoma
title_full The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Extrapulmonary Small Cell Carcinoma
title_fullStr The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Extrapulmonary Small Cell Carcinoma
title_full_unstemmed The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Extrapulmonary Small Cell Carcinoma
title_short The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Extrapulmonary Small Cell Carcinoma
title_sort role of immune checkpoint inhibitors in the treatment of extensive-stage extrapulmonary small cell carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325398/
https://www.ncbi.nlm.nih.gov/pubmed/32617246
http://dx.doi.org/10.7759/cureus.8862
work_keys_str_mv AT alyragia theroleofimmunecheckpointinhibitorsinthetreatmentofextensivestageextrapulmonarysmallcellcarcinoma
AT guptasachin theroleofimmunecheckpointinhibitorsinthetreatmentofextensivestageextrapulmonarysmallcellcarcinoma
AT potdarrashmika theroleofimmunecheckpointinhibitorsinthetreatmentofextensivestageextrapulmonarysmallcellcarcinoma
AT alyragia roleofimmunecheckpointinhibitorsinthetreatmentofextensivestageextrapulmonarysmallcellcarcinoma
AT guptasachin roleofimmunecheckpointinhibitorsinthetreatmentofextensivestageextrapulmonarysmallcellcarcinoma
AT potdarrashmika roleofimmunecheckpointinhibitorsinthetreatmentofextensivestageextrapulmonarysmallcellcarcinoma

Ejemplares similares